Literature DB >> 6141587

Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants.

M K Menon, C A Vivonia, V G Haddox.   

Abstract

In mice, amantadine pretreatment (150 mg/kg, but not 10 mg/kg, 2 h prior to testing) markedly inhibited the locomotor stimulation produced by submaximal doses of d-amphetamine, amfonelic acid, methylphenidate, caffeine, memantin, phencyclidine, and cocaine. A 50-mg/kg dose was ineffective in blocking the effects of caffeine and memantin, but blocked the responses to the other five stimulants. Amantadine did not modify the locomotor stimulant effect of apomorphine in reserpinized mice. These results indicate that amantadine acts as a presynaptic antagonist to the above seven stimulants. Even the highest dose of amantadine did not modify the hyperactivity induced in mice by morphine and levorphanol. This result is consistent with evidence showing opiate actions at postsynaptic striatal neurons, sites where presumably amantadine is unable to exert an antagonist effect. Amantadine did not modify the central depressant effects of ethyl alcohol and pentobarbital. Amantadine could be of value as a pharmacological tool in understanding the mode of action of central stimulants, and in the management of stimulant abuse. The present data do not support the currently held view that the antiparkinsonism effect of amantadine results from its ability to potentiate the central effects of dopamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141587     DOI: 10.1007/bf00426387

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Effect of amantadine on the rate of dopamine synthesis in rat corpus striatum.

Authors:  S Bariletto; E Dollar; F Leitz
Journal:  J Neurochem       Date:  1975-08       Impact factor: 5.372

2.  Monoamine synthesis and caffeine-induced locomotor activity.

Authors:  B C White; C C Simpson; J E Adams; D Harkins
Journal:  Neuropharmacology       Date:  1978-07       Impact factor: 5.250

3.  Interactions of L-dopa and amantadine in patients with Parkinsonism.

Authors:  B Cox; G Danta; H Schnieden; G M Yuill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-06       Impact factor: 10.154

4.  Blockade of the central effects of d-amphetamine sulfate by amantadine hydrochloride.

Authors:  M K Menon; W G Clark; R M Fleming
Journal:  Eur J Pharmacol       Date:  1973-03       Impact factor: 4.432

5.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

6.  Effects of narcotic analgesics upon the locomotor activity and brain catecholamine content of the mouse.

Authors:  C R Rethy; C B Smith; J E Villarreal
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

7.  Striatal opiate receptors: pre- and postsynaptic localization.

Authors:  L C Murrin; J T Coyle; M J Kuhar
Journal:  Life Sci       Date:  1980-09-29       Impact factor: 5.037

8.  Comparative effects of amantadine and amfonelic acid on dopamine metabolism in rat brain.

Authors:  R W Fuller; H D Snoddy; K W Perry
Journal:  Brain Res Bull       Date:  1981-02       Impact factor: 4.077

9.  Interaction between phencyclidine (PCP) and GABA-ergic drugs: clinical implications.

Authors:  M K Menon; W G Clark; C Vivonia
Journal:  Pharmacol Biochem Behav       Date:  1980-01       Impact factor: 3.533

10.  Dopamine: release from the brain in vivo by amantadine.

Authors:  P F Von Voigtlander; K E Moore
Journal:  Science       Date:  1971-10-22       Impact factor: 47.728

View more
  2 in total

1.  Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice.

Authors:  Tobie Escher; Stanford B Call; Charles D Blaha; Guy Mittleman
Journal:  Psychopharmacology (Berl)       Date:  2006-07-12       Impact factor: 4.530

2.  Evidence for monoaminergic involvement in triadimefon-induced hyperactivity.

Authors:  K M Crofton; V M Boncek; R C MacPhail
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.